Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade F 16.48 3.58% 0.57
GLYC closed up 3.58 percent on Thursday, July 19, 2018, on 60 percent of normal volume.

Earnings due: Aug 2

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical GLYC trend table...

Date Alert Name Type % Chg
Jul 19 Bullish Engulfing Bullish 0.00%
Jul 18 Hammer Candlestick Bullish 3.58%
Jul 18 Lizard Bullish Bullish Day Trade Setup 3.58%
Jul 18 Doji - Bullish? Reversal 3.58%
Jul 16 Downside 200 DMA Break Bearish 3.71%
Jul 16 Overbought Stochastic Strength 3.71%
Jul 13 50 DMA Resistance Bearish -3.74%
Jul 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.74%
Jul 13 Upside 200 DMA Break Bullish -3.74%
Jul 13 Overbought Stochastic Strength -3.74%

Older signals for GLYC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Is GLYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.05
52 Week Low 10.06
Average Volume 536,532
200-Day Moving Average 17.0104
50-Day Moving Average 17.0366
20-Day Moving Average 15.974
10-Day Moving Average 16.566
Average True Range 0.7914
ADX 16.23
+DI 20.3847
-DI 22.8772
Chandelier Exit (Long, 3 ATRs ) 14.8758
Chandelier Exit (Short, 3 ATRs ) 16.5842
Upper Bollinger Band 17.5042
Lower Bollinger Band 14.4438
Percent B (%b) 0.67
BandWidth 19.158633
MACD Line -0.1044
MACD Signal Line -0.1724
MACD Histogram 0.068
Fundamentals Value
Market Cap 539.27 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -12.30
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.79
Resistance 3 (R3) 17.66 17.09 17.57
Resistance 2 (R2) 17.09 16.76 17.16 17.49
Resistance 1 (R1) 16.79 16.56 16.94 16.92 17.42
Pivot Point 16.22 16.22 16.30 16.29 16.22
Support 1 (S1) 15.92 15.89 16.07 16.05 15.54
Support 2 (S2) 15.35 15.69 15.42 15.47
Support 3 (S3) 15.05 15.35 15.39
Support 4 (S4) 15.18